Qureator extends its sincere appreciation to The BIO for its in-depth reporting on our landmark FDA IND approval achieved without animal PoC data. The coverage underscores a transformative moment for the global drug-development landscape and highlights the pivotal collaboration between Qureator and SillaJen.
Qureator announced the world’s first FDA Investigational New Drug (IND) approval for an oncology therapy, SillaJen’s BAL0891, based solely on efficacy data from our human vascularized organ-on-a-chip (vTIME) platform, successfully replacing traditional animal studies.
Qureator’s pioneering work in advanced 3D disease modeling was recently spotlighted by the Korean Economic Daily in coverage of our collaboration with SillaJen Inc.
Qureator is proud to announce that its pioneering work on age-related macular degeneration (AMD) has been featured as the cover article in Advanced Materials Technologies.
Qureator is proud to be featured in a recent update from our collaborator, Professor Jonathan Sexton of the University of Michigan, highlighting the use of our Curiochip™ microphysiologic system in a cutting-edge platform for predicting drug-induced liver injury (DILI).
Qureator is excited to announce a new research collaboration with SillaJen Inc. to evaluate combination immunotherapy using BAL0891, a dual TTK/PLK1 inhibitor, with PD-1 immune checkpoint inhibitors.
Qureator was recently featured in The Chosun Daily for its cutting-edge human disease modeling platform that replicates complex tissue microenvironments using organ-on-a-chip technology.